Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGOS-LS
NCT06773910Phase 2Active, not recruiting
- Sponsor
- SCRI Development Innovations
- Start
- Mar 2025
- Primary completion
- May 2032
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bms-986012 + nivolumab in small cell lung cancer (SCLC) (2 arms), sponsored by SCRI Development Innovations. Primary endpoint: Overall Survival up to 5 years. Started Mar 2025; status: active, not recruiting.
02
Drugs
bms-986012 + nivolumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06773910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06773910.